Let's Find Opportunities Overseas
Tag: Funanc1alEdge
Tilray Brands But No Sunshine: Can Shareholders Finally Fly High?
Tilray’s stock is flying higher… again. But after years of false starts, net losses, and wild dreams, is this the real lift-off—or just another high followed by a low? Find out what’s cooking with Tilray’s drinks, cannabis brands, AI strategy, and why its reverse stock split is both approved and… on pause.
Crispr Therapeutics AG (CRSP) Insider Buys Big — Should You?
🚨 CRISPR Therapeutics just got two massive insider injections — and not the lab kind. Add in CASGEVY® expansion, gene therapy milestones, and a $1.7B cash pile, and you might want to splice this one into your portfolio.
Alcon Inc. (ALC): Fully Valued, Even Through a Different Lens — Still Worth Wearing
Swiss-based Alcon leads the eye-care game—but with a sky-high P/E, are investors seeing clearly or dreaming big? AKO Capital sure thinks it’s visionary. We look closer. 👀🇨🇭
Teva Pharma: The Funds Believe. Should You?
Hedge fund legend Stanley Druckenmiller just upped his stake in TEVA by 65%—and he’s not alone. With 9 straight quarters of growth, rising biosimilar momentum, and a “Pivot to Growth” strategy in motion, Teva might finally be ready for its rerating. We still like the sandals, but the stock may be worth more than a hike.
Lululemon: Don’t Sweat the Small Stuff
Lululemon shares just faceplanted—down 20%—but insiders (and leggings lovers) may see a bounce coming. From CEO buys to global growth and cult-level brand loyalty, here’s why LULU might be worth the stretch. 🧘💰